摘要
目的探讨左-卡尼汀对维持性血液透析患者脂质代谢的影响。方法对63例维持性血液透析患者于每次透析结束后静脉注射左-卡尼汀1g,共治疗12周。治疗前后测定血清总胆固醇(TC)、甘油三酯(TG)、高密度脂蛋白胆固醇(HDLC)及其亚组分(HDL2-C,HDL3-C)、低密度脂蛋白胆固醇(LDL-C)、极低密度脂蛋白胆固醇(VLDL-C)等指标。选择同期正常对照组30例。结果治疗组患者血清TG、VLDL-C明显高于对照组,差异有统计学意义(P〈0.01),HDL-C、HDL2-C明显低于对照组,差异有统计学意义(P〈0.01),而TC、HDL3-C和LDL-C两组比较无明显差异(P〉0.05)。治疗后治疗组血清TG、VLDL-C水平下降,治疗前后比较,差异有统计学意义(P〈0.05,P〈0.01),HDL-C、HDL2-C明显增加(P〈0.01),而TC、HDL3-C和LDL-C水平无明显变化(P〉0.05)。结论左-卡尼汀通过降低血清TG、VLDL-C水平,提高HDL-C、HDL2-C浓度改善维持性血液透析患者脂质代谢异常。
Objective To observe the effect of L-carnitine on lipid metabolism in maintenance hemodialysis (MILD) patients. Methods Sixty-three patients who were on MHD were enrolled as a treatment group and treated with intravenous L-carnitine (1 g at the end of each dialysis session) for 12 weeks. The serum levels of total cholesterol (TC), triglyceride (TG), high density lipoprotein cholesterol (HDL-C) and its subcomponents (HDL2-C, HDL3-C), low density lipoprotein cholesterol (LDL-C), and very low density lipoprotein cholesterol (VLDL-C) were measured pre- and post-treatment in treatment group. At the same time, 30 normal healthy people served as a control group. Results The serum levels of TG and VLDL-C were higher significantly, HDL-C and HDL2-C were lower remarkably in the treatment group than in the control group (P〈0. 01). However, there was no significant difference in serum levels of TC, HDL3-C and LDL-C between the two groups (P〉0. 05). After treatment, the serum levels of TG and VLDL-C were decreased remarkably and HDL-C and HDL2-C increased significantly in the treatment group (P〈0. 05 or P〈0. 01), but there was no significant difference in serum levels of TC, HDL3-C and LDL-C pre- and post-treatment (P〉0. 05). Conclusions Treatment of MHD patients with supplementary L-carnitine improves dyslipidemia by reducing serum levels of TG, VLDL-C and increasing serum levels of HDL-C and HDL2-C.
出处
《临床肾脏病杂志》
2008年第6期261-263,共3页
Journal Of Clinical Nephrology